Your weekly roundup of the latest news from Drug Topics®.
Study finds growth in three years after CDC guideline for primary care clinicians.
The risk could allow unauthorized users to change insulin levels.
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis to understand how they are usually treated with Dupixent in the real world.
Hospitalization, disability, having private high-deductible, Medicare Advantage, or no coverage were risk factors associated with medical debt.
Research indicates that using an open-source automated insulin delivery systems can lead to greater glycemic control.
FDA Approves Second Formulation of Humira Biosimilar Cyltezo
May 1st 2024According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”